📰 **Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug**

Key PointsACT Capital Management acquired 174,250 ALMS shares in the first quarter, with an estimated trade value of $4.36 million based on average first-quarter pricing.

🔗 https://www.nasdaq.com/articles/why-one-funds-4-million-alumis-buy-looks-bet-breakthrough-autoimmune-drug

#markets #news